Your browser doesn't support javascript.
loading
Combination product of dermal matrix, preconditioned human mesenchymal stem cells and timolol promotes wound healing in the porcine wound model.
Yang, Hsin-Ya; Fierro, Fernando; Yoon, Daniel J; Gallegos, Anthony; Osborn, Stephanie L; Nguyen, Alan V; Peavy, Thomas R; Ferrier, William; Talken, Linda; Ma, Betty W; Galang, Kristopher G; Medina Lopez, Andrea; Fregoso, Daniel R; Stewart, Heather; Kurzrock, Eric A; Soulika, Athena M; Nolta, Jan A; Isseroff, R Rivkah.
Afiliación
  • Yang HY; Department of Dermatology, School of Medicine, University of California Davis Health System, Sacramento, California, USA.
  • Fierro F; Department of Cell Biology and Human Anatomy, University of California Davis Health System, Sacramento, California, USA.
  • Yoon DJ; Stem Cell Program, Department of Internal Medicine, University of California Davis Health System, Sacramento, California, USA.
  • Gallegos A; Department of Dermatology, School of Medicine, University of California Davis Health System, Sacramento, California, USA.
  • Osborn SL; Department of Dermatology, School of Medicine, University of California Davis Health System, Sacramento, California, USA.
  • Nguyen AV; Stem Cell Program, Department of Internal Medicine, University of California Davis Health System, Sacramento, California, USA.
  • Peavy TR; Department of Urologic Surgery, School of Medicine, University of California Davis Health System, Sacramento, California, USA.
  • Ferrier W; Department of Dermatology, School of Medicine, University of California Davis Health System, Sacramento, California, USA.
  • Talken L; Institute for Pediatric Regenerative Medicine, Shriners Hospital for Children Northern California, Sacramento, California, USA.
  • Ma BW; Department of Biological Sciences, California State University, Sacramento, Sacramento, California, USA.
  • Galang KG; Large Animal Survival Surgery Facility, Stem Cell Program, University of California Davis Health System, Sacramento, California, USA.
  • Medina Lopez A; Large Animal Survival Surgery Facility, Stem Cell Program, University of California Davis Health System, Sacramento, California, USA.
  • Fregoso DR; Campus Veterinary Services Clinic, Office of Research, University of California, Davis, Davis, California, USA.
  • Stewart H; Campus Veterinary Services Clinic, Office of Research, University of California, Davis, Davis, California, USA.
  • Kurzrock EA; Residency Program in Laboratory Animal/Primate Medicine, School of Veterinary Medicine, University of California, Davis, Davis, California, USA.
  • Soulika AM; Department of Dermatology, School of Medicine, University of California Davis Health System, Sacramento, California, USA.
  • Nolta JA; Department of Dermatology, School of Medicine, University of California Davis Health System, Sacramento, California, USA.
  • Isseroff RR; Stem Cell Program, Department of Internal Medicine, University of California Davis Health System, Sacramento, California, USA.
J Biomed Mater Res B Appl Biomater ; 110(7): 1615-1623, 2022 07.
Article en En | MEDLINE | ID: mdl-35099112
A combination product of human mesenchymal stem/stromal cells (MSCs) embedded in an extracellular matrix scaffold and preconditioned with hypoxia and the beta-adrenergic receptor antagonist, timolol, combined with sustained timolol application post implantation, has shown promising results for improving wound healing in a diabetic mouse model. In the present study, we extend those findings to the more translatable large animal porcine wound model and show that the combined treatment promotes wound reepithelialization in these excisional wounds by 40.2% and increases the CD31 immunostaining marker of angiogenesis compared with the matrix control, while maintaining an accumulated timolol plasma concentration below the clinically safe level of 0.3 ng/mL after the 15-day course of topical application. Human GAPDH was not elevated in the day 15 wounds treated with MSC-containing device relative to wounds treated with matrix alone, indicating that the xenografted human MSCs in the treatment do not persist in these immune-competent animals after 15 days. The work demonstrates the efficacy and safety of the combined treatment for improving healing in the clinically relevant porcine wound model.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Trasplante de Células Madre Mesenquimatosas / Células Madre Mesenquimatosas Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: J Biomed Mater Res B Appl Biomater Asunto de la revista: ENGENHARIA BIOMEDICA Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Trasplante de Células Madre Mesenquimatosas / Células Madre Mesenquimatosas Tipo de estudio: Prognostic_studies Límite: Animals / Humans Idioma: En Revista: J Biomed Mater Res B Appl Biomater Asunto de la revista: ENGENHARIA BIOMEDICA Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos